1.The Relationship between MDR1 Polymorphisms and the Response to Etoposide/Cisplatin Combination Chemotherapy in Small Cell Lung Cancer.
Ji Woong SOHN ; Shin Yup LEE ; Su Jung LEE ; Hyo Sung JEON ; Jae Hee LEE ; Jae Hyung PARK ; Eun Jin KIM ; Seung Ick CHA ; Chang Ho KIM ; Young Mo KANG ; Jae Tae LEE ; Tae Hoon JUNG ; Jae Yong PARK
Tuberculosis and Respiratory Diseases 2005;58(2):135-141
No abstract available.
Drug Therapy, Combination*
;
Small Cell Lung Carcinoma*
2.Alternating non-cross-resistant chemotherapy with CAV(cyclophosphamide, adriamycin, vincristine) and EP(etoposide, cisplatin) in small cell lung cancer.
Chang Hak SOHN ; Bong Choon LEE ; Hyoung Kyu SHIN ; Key Jung CHO
Journal of the Korean Cancer Association 1992;24(4):570-576
No abstract available.
Doxorubicin*
;
Drug Therapy*
;
Small Cell Lung Carcinoma*
3.actate Dehydrogenase (LDH) as a Tumor Marker for Non-small Cell Lung Cancer.
Cancer Research and Treatment 2002;34(5):339-344
PURPOSE: To determine the prognostic value of pre- treatment serum LDH levels and the LDH isoenzyme pattern for non-small cell lung cancer, and to determine the relationship between the response to chemotherapy and the changes in serum LDH levels following chemotherapy MATERIALS AND METHODS: Patients with pathologically confirmed non-small cell lung cancer were entered onto this study. Their serum LDH levels were assessed prior to chemotherapy, with the LDH isoenzyme being assessed in patients with high initial serum LDH levels. The serum LDH levels were re-assessed following 2 cycles of chemotherapy. The relationship between the response to chemotherapy, pre-treatment serum LDH levels and LDH isoenzyme pattern and the changes in serum LDH levels, following chemotherapy, were evaluated. RESULTS: 49 patients were entered onto this study. The pre-treatment serum LDH levels were normal in 26 patients, and elevated in 23. The LDH isoenzyme was evaluated in 15 patients, with LDH2 being elevated the most frequently. The response rate to chemotherapy was 42.9% in all 42 patients able to be evaluated, 45.8% in patients with normal serum LDH levels and 41.2% in patients with elevated serum LDH levels. This difference was not statistically significant (p=0.767). The median survival was 37 weeks in all patients able to be evaluated, 38 weeks in those with normal serum LDH levels and 31 weeks in those with elevated serum LDH levels. These differences were not statistically significant (p=0.202). The patients with normal serum LDH levels following chemotherapy were more responsive to chemotherapy than those with elevated serum LDH levels following chemotherapy (response rate 51.4% vs. 0%, p=0.027). CONCLUSION: The LDH2 are most commonly elevated in non small cell lung cancer patients. The pre-treatment serum LDH levels do not reflect the prognosis accurately. The serum LDH levels following chemotherapy are associated with the response to chemotherapy.
Carcinoma, Non-Small-Cell Lung*
;
Drug Therapy
;
Humans
;
Oxidoreductases*
;
Prognosis
;
Small Cell Lung Carcinoma
4.Marked Improvement of Lambert-Eaton Myasthenic Syndrome with the Chemotherapy of Small Cell Lung Carcinoma.
Dae Soo SHIN ; Hyun Young PARK ; Kwang Ho CHO
Journal of the Korean Neurological Association 2006;24(1):95-97
No abstract available.
Drug Therapy*
;
Lambert-Eaton Myasthenic Syndrome*
;
Small Cell Lung Carcinoma*
5.Role of Radiation Therapy for Non-small Cell Lung Cancer: Focused on Stereotactic Ablative Radiation Therapy in Stage I.
Hanyang Medical Reviews 2014;34(1):45-50
Radiation therapy has played a key role, together with surgery and systemic chemotherapy, in treating in all stages of non-small cell lung cancer. We have witnessed remarkable improvements in radiation therapy techniques, with the innovations in hardware and software. Stereotactic ablative radiation therapy, which can deliver high radiation dose focused to small target volume, represents one of the state-of-the-art radiation therapy techniques. The technical development of radiation therapy and the role of stereotactic ablative radiation therapy in treating inoperable stage I non-small cell lung cancer are briefly reviewed.
Carcinoma, Non-Small-Cell Lung*
;
Drug Therapy
;
Radiotherapy
;
Stereotaxic Techniques
6.Total necrosis of small cell lung carcinoma after combination chemotherapy and radiotherapy: one case report-.
Doo Yun LEE ; Hae Kyoon KIM ; Gi Man BAE
Journal of the Korean Cancer Association 1992;24(1):180-186
No abstract available.
Drug Therapy, Combination*
;
Necrosis*
;
Radiotherapy*
;
Small Cell Lung Carcinoma*
7.High VPP combination chemotherapy for advanced non-small cell lung cancer.
Seok Cheol HONG ; Pyo Seong HAN ; Jong Jin LEE ; Hai Jeong CHO ; Ju Ock KIM ; Sun Young KIM
Tuberculosis and Respiratory Diseases 1993;40(4):367-377
No abstract available.
Carcinoma, Non-Small-Cell Lung*
;
Drug Therapy, Combination*
8.Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future.
Cancer Research and Treatment 2003;35(4):279-280
No abstract available.
Carcinoma, Non-Small-Cell Lung*
;
Drug Therapy*
;
Hope*
9.Alterating combination chemotherapy of cyclophosphamide, adriamycin, and vincristine(CAV) with etoposide and cisplatin(EP) in small cell lung cancer.
Jong Wook LEE ; Jin Hyoung KANG ; Jong Youl JIN ; Han Lim MOON ; Young Seon HONG ; Hoon Kyo KIM ; Kyung Shik LEE ; Dong Jip KIM ; Sei Chul YOON
Journal of the Korean Cancer Association 1991;23(4):790-797
No abstract available.
Cyclophosphamide*
;
Doxorubicin*
;
Drug Therapy, Combination*
;
Etoposide*
;
Small Cell Lung Carcinoma*
10.Primary Small Cell Carcinoma of the Kidney.
Young Seog SO ; Dong Hoon LIM ; Seung BAIK ; Joon RHO ; Chul Sung KIM
Korean Journal of Urology 2004;45(3):283-286
Small cell carcinoma is a malignant neoplasm, which has neuroendocrine and epithelial features immunohistochemically and ultrastructurally. Primary small cell carcinoma originating from the kidneys is extremely rare, aggressive and lethal. Approximately half the reported cases show combined features of transitional cell carcinoma. A case of primary renal small cell carcinoma without features of transitional cell carcinoma is reported, which was studied under light microscopy and by immunohistochemistry and treated by retroperitoneal laparoscopic radical nephrectomy and chemotherapy.
Carcinoma, Small Cell*
;
Carcinoma, Transitional Cell
;
Drug Therapy
;
Immunohistochemistry
;
Kidney*
;
Microscopy
;
Nephrectomy
Result Analysis
Print
Save
E-mail